Hemp Oil

Phase 1Small molecule

GGregory L Smith, MD, MPH

Hemp Oil is one of 28 small molecule programs targeting Androgenetic Alopecia. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Androgenetic AlopeciaActive, not recruiting

Androgenetic AlopeciaPhase 1

Active, not recruiting

Competition

Competitive Landscape

62 competitors in Androgenetic Alopecia

#DrugCompanyPhaseTrials

Propecia

OOrganon and Co

Approved

7 2

Depakote

Zyrtec

2 4

Avodart

Akero Therapeutics

Phase 3

4 5

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Phase 2

—6

XEOMIN

MMerz Pharmaceuticals GmbH

Zolymbus

1 8

Platelet Rich Plasma

ZZagazig University

Phase 2

2 9

Lactobacillus Reuteri

TTulane University School of Medicine

Phase 2

1 10

Stem Cells

KKang Stem Biotech Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Androgenetic Alopecia1 trial

Androgenetic Alopecia Treatment Using Varin and Cannabidiol Rich Topical Hemp Oil: A Case Series

Unknown status·GGregory L Smith, MD, MPH·Phase 1·NCT04842383·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Hemp Oil. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hemp Oil compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hemp Oil. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Gregory L Smith, MD, MPH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: GGregory L Smith, MD, MPH

Hemp Oil

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Androgenetic Alopecia1 trial

References

Drug Info

Quick Facts

Related News